Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Thu 13:11
BRIEF-Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease Oct 29 (Reuters) - Abbott Laboratories ABT.N:
ABBOTT INITIATES PIVOTAL TRIAL FOR CEPHEA™ DEVICE, AN INNOVATIVE TREATMENT FOR MITRAL HEART VALVE DISEASE
Source text: ID:nPn3y668na
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Abbott Laboratories
See all newsPerrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement
Brief: Catheter Precision Announces Publication Of Comparative Study Showing Locket Outperforms Abbott’S Perclose Internal Vascular Closure Device